Literature DB >> 10370639

Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.

T Griga1, E Voigt, B Gretzer, F Brasch, B May.   

Abstract

BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Recent studies have shown significantly increased VEGF serum levels in patients with active Crohn's disease and ulcerative colitis. The origin of the circulating VEGF is not yet completely described. The present investigation examines the VEGF production of colonic mucosa in consideration of mucosal disease activity in patients with inflammatory bowel disease.
METHODOLOGY: Fifteen patients with inflammatory bowel disease were studied, 9 patients with Crohn's disease and 6 patients with ulcerative colitis. Biopsies were taken from endoscopically inflamed and non-inflamed colonic mucosa. Therefore, an analysis of the spontaneous VEGF production of cultured biopsies without stimulus and of the histological grade of inflammation scored on a scale of 0-3 (normal mucosa--severe chronic colitis) were performed. Eight patients with irritable bowel syndrome served as controls. VEGF levels in the supernatant of cultured mucosal biopsies were measured using an enzyme linked immunosorbent assay.
RESULTS: VEGF production is expressed as pg/mg wet weight of the biopsies. Inflamed mucosa of patients with active ulcerative colitis (16.27 +/- 10.39, p = 0.003, n = 6) and active Crohn's disease (9.88 +/- 5.98, p < 0.012, n = 9) showed a significantly higher spontaneous production of VEGF by colonic mucosa than normal mucosa of controls (3.16 +/- 1.63, n = 8). In addition, there was an increased unstimulated VEGF production by cultured inflamed mucosa of patients with Crohn's disease compared with non-inflamed mucosa (3.88 +/- 3.66, p < 0.015, n = 9). In both Crohn's disease and ulcerative colitis, there was no significant difference between VEGF production by non-inflamed mucosa and normal mucosa of controls.
CONCLUSIONS: The present study identifies the intestinal mucosa as one of the origins of the elevated VEGF serum levels in patients with active inflammatory bowel disease and verifies the findings of recent studies about the importance of VEGF in Crohn's disease and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370639

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  19 in total

1.  Structural adaptations in the murine colon microcirculation associated with hapten-induced inflammation.

Authors:  Dino J Ravnic; Moritz A Konerding; Akira Tsuda; Harold T Huss; Tanja Wolloscheck; Juan P Pratt; Steven J Mentzer
Journal:  Gut       Date:  2006-11-17       Impact factor: 23.059

2.  PAF receptor antagonist Ginkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer.

Authors:  Lei Sun; Zhen He; Jia Ke; Senmao Li; Xianrui Wu; Lei Lian; Xiaowen He; Xiaosheng He; Jiancong Hu; Yifeng Zou; Xiaojian Wu; Ping Lan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease.

Authors:  A Giatromanolaki; E Sivridis; E Maltezos; D Papazoglou; C Simopoulos; K C Gatter; A L Harris; M I Koukourakis
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

5.  Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease.

Authors:  F Magro; F Araujo; P Pereira; E Meireles; M Diniz-Ribeiro; F Tavarela Velosom
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

6.  Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.

Authors:  Lin Wang; Shengnan Wang; Aijuan Xue; Jieru Shi; Cuifang Zheng; Ying Huang
Journal:  Inflammation       Date:  2020-11-18       Impact factor: 4.092

7.  Vascular endothelial growth factor in inflammatory bowel disease.

Authors:  Andreas Kapsoritakis; Aekaterini Sfiridaki; Efstratios Maltezos; Kostantinos Simopoulos; Alexandra Giatromanolaki; Efthimios Sivridis; Michael I Koukourakis
Journal:  Int J Colorectal Dis       Date:  2003-05-22       Impact factor: 2.571

8.  Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production.

Authors:  Ana Teresa Carvalho; Heitor Souza; Antonio Jose Carneiro; Morgana Castelo-Branco; Kalil Madi; Alberto Schanaider; Flavia Silv; Fernando Antonio Pereira Junior; Marcia G Pereira; Claudio Tortori; Ilana Dines; Jane Carvalho; Eduardo Rocha; Celeste Elia
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

9.  Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis.

Authors:  Yesuf Taha; Yngve Raab; Anders Larsson; Marie Carlson; Lars Lööf; Bengt Gerdin; Magnus Thörn
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 10.  Advances in nutritional therapy in inflammatory bowel diseases: Review.

Authors:  Andrzej Wędrychowicz; Andrzej Zając; Przemysław Tomasik
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.